Xavier Siwe Noundou
I am Xavier Siwe Noundou and recently graduated with a PhD in Chemistry in the Department of Applied Chemistry at the University of Johannesburg under the supervision of Professor Rui Krause. Currently, I am a Post-Doctoral Fellow and Manager of Prof Krause’s Lab. My main research focus includes: medicinal natural products (MNP), organic synthesis (OS), drug delivery systems (DDS), and stimuli-responsive systems (SRS). Most of the applications of my research work are related to the development and treatment of diseases, especially neglected diseases and Poverty-Related Infectious Diseases (PRIDs) including cancer, tuberculosis, malaria, HIV-AIDS, diabetes and other microbial infections. The aim of these projects is to improve the activity of new bioactive or existing compounds against diseases of our interest. My current project is dealing with the development of new treatment for cancer.
Cancer is one of the diseases where all the current treatments are not good due to the side effects, bio-availability, fast degradation and low aqueous solubility of many drugs. We can therefore use nanotechnology and DDS to bring a solution to these drawbacks. Over the past decades, a great interest has been shown on the use of nanoparticles (NP) like gold nanoparticle (AuNP) to treat cancer due to their properties to specifically target cancer cells. The destination of these NP in the body or tissue is however not known precisely yet. So there are concerns that AuNP could accumulate in the tissue and become very difficult to be excreted. Due to their small size it is not always possible to determine the path followed by the NP even with a very powerful electron microscope. Therefore if we want to deliver a drug into a cancer cell, we need to find a method of tracing where the drug goes after being administered in the cell. The surface of AuNP is quite large and can be coated with a number of molecules and then be loaded in the matrices of polymers such as chitosan or cyclodextrin.
Such DDS can be traced in the cells and offer the possibility to reduce the side effects, improve the bio-availability and low aqueous solubility as well as decrease the fast degradation of many drugs.
I recently attended the 23rd Biennial European Association for Cancer Research Congress, 5th–8th July 2014, Munich, Germany, the biggest meeting on cancer in Europe where more than 2000 researchers gathered to share and discuss their lastest findings on the development of new treatments for cancer. During my stay in Germany, I was invited by our collaborator, Prof.Dr. Ihmels Heiko from Universität Siegen, to present a seminar to his research group and the Department of Chemistry.
Last Modified :Fri, 04 Aug 2017 13:12:19 SAST